Kornimate/medical-research-clean huggingface dataset:
effects of prehabilitation on postoperative recovery

Conditions: Lung Cancer

Summary: the study to be carried out in the istanbul faculty of medicine department of anesthesiology was planned as a randomized, prospective study. patients who will undergo lung resection will be included in the study. patients were randomized into two groups: intervention group includes patients who are rehabilitated preoperatively (prehabilitation), control group includes patients who are routinely recommended preoperative exercise, alcohol and smoking cessation. prehabilitation consists of respiratory muscle exercise and walking is recommended to intervention group. postoperative recovery will be questioned with quality of recovery-15 (qor-15) on the 2nd day and 1st month. the intensive care unit admission, postoperative pulmonary complications and length of hospital stay will be recorded.

the study to be carried out in the istanbul faculty of medicine department of anesthesiology was planned as a randomized, prospective study. patients who will undergo lung resection will be included in the study. patients will be informed about the study and their written consent will be obtained. patients who do not give consent will not be included in the study. routine preoperative evaluation including detailed history (daily physical activity, clinical complaints at rest or exertion, if any) and physical examination will be performed on the patients. patients were randomized into two groups: intervention group includes patients who are rehabilitated preoperatively (prehabilitation), control group includes patients who are routinely recommended preoperative exercise, alcohol and smoking cessation. preoperative exercise, alcohol and smoking cessation are recommended to all patients. prehabilitation consists of respiratory muscle exercise with inspiratory muscle trainer (two times a day) and walking (5000steps/day) is recommended to intervention group. hospitalized patients are followed up with daily visits, and patients who are at home are followed up by phone call. all patients' induction of anesthesia and maintenance were similar. postoperative recovery will be questioned with quality of recovery-15 (qor-15) on the 2nd day (as primary outcome) and 1st month. the duration of anesthesia, surgery duration, intensive care unit admission, postoperative pulmonary complications and length of hospital stay will be recorded.

Eligibility criteria:
inclusion criteria: * asa physical status classification system score 1-3 patients * patients who underwent lung resection * patients who agreed to participate in the study and gave written informed consent exclusion criteria: * re-operation * emergency operations * patients with psychiatric drug use * unability for physical exercise

Keywords: prehabilitation quality of recovery lung resection
comparıson of electromyography results before and after vıtamın d treatment in patıents wıth carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Vitamin D Deficiency

Summary: therefore, we aimed to evaluate the effectiveness of vitamin d replacement therapy on pain, electrophysiological parameters, ultrasonographic measurement results and functional status scales in cts patients with low serum vitamin d levels.

introduction: apart from its effect on bone health, vitamin d is also known to have beneficial effects on the neurological system. in studies, vitamin d levels were found to be low in patients with carpal tunnel syndrome (cts). however, studies examining the effects of vitamin d replacement on cts are limited. therefore, we aimed to evaluate the effectiveness of vitamin d replacement therapy on pain, electrophysiological parameters, ultrasonographic measurement results and functional status scales in cts patients with low serum vitamin d levels. materials and methods: our study was planned as an observational and analytical prospective. vitamin d loading therapy was given to patients with serum vitamin d levels below 20ng/ml and mild-moderate cts detected by electroneuromyography (enmg). patients with vitamin d levels above 20 ng/ml after 8 weeks were included in the study. each patient was given a rest splint and exercise program. patients were evaluated before and 3 months after treatment with electrophysiological, ultrasonographic, vas, pinch-grip strength, two-point discrimination, monofilament test and boston symptom severity scale.

Eligibility criteria:
inclusion criteria: * 18-70 years old male or female gender * those with mild to moderate cts according to enmg, * vitamin d level \<20. exclusion criteria: * severe cts according to enmg * thenar region atrophy * diabetes mellitus, * rheumatoid arthritis, * hyperthyroidism, * hypothyroidism * traumatic nerve injury, history of surgery * polyneuropathy * pregnancy * severe psychiatric illness * poor orientation and cooperation, * injection (corticosteroid, ozone, stem cell...) applied for cts treatment within 3 months

Keywords: carpal tunnel syndrome vitamin d deficiency electrophysiologia
efficacy study of vitamin d to treat contrast-induced nephropathy

Conditions: Contrast-induced Nephropathy

Summary: the investigators planned to research the effect of vitamin d supplementation on the incidence of contrast-induced nephropathy in patients undergoing coronary angiography.

vitamin d is primarily generated in the skin, in response to direct absorption of ultraviolet b radiation. vitamin d can also be obtained through fortified foods and oral supplements. contrast-induced nephropathy (cin) is a generally reversible form of acute kidney injury that occurs mostly within 2-3 days of exposure to contrast medium (cm). the estimated incidence of cin ranges from 2%-50%, and coronary angiography (cag) or percutaneous coronary intervention (pci), or both, are associated with cin in about half of cases. recently low vitamin d status has been shown to be associated with increased risk of cin. however, its effects on cin patients remain unclear. the investigators planned to determine the efficacy of vitamin d on the incidence of contrast-induced nephropathy in patients undergoing coronary angiography. this study may shed light as to whether oral vitamin d supplementation can be an adjunct therapy in cin patients.

Eligibility criteria:
inclusion criteria: * the main inclusion criteria were patients who underwent coronary angiography. exclusion criteria: * the exclusion criteria were as follows: patients with chronic renal failure, chronic liver disease, bone disorders, and/or thyroid disorders. * patients were also excluded if they were taking vitamin d3 tablets or other lipid-regulating drugs.
study evaluating the drug interaction potential of luliconazole cream 1% in participants with tinea pedis and tinea cruris

Conditions: Tinea Pedis; Tinea Cruris

Summary: this is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as an inhibitor of cytochrome p2c19 (cyp2c19) as measured by circulating levels of omeprazole before and after treatment with a maximum dose of luliconazole cream 1% in participants with moderate to severe tinea pedis and tinea cruris.


Eligibility criteria:
inclusion criteria: * participants with a clinical diagnosis of moderate to severe interdigital tinea pedis, as defined by a physician's global assessment (pga) score of 2 or 3 on both feet, and moderate to severe tinea cruris, as defined by a pga score of 2 or 3 * participants with a mycological diagnosis of tinea pedis and tinea cruris confirmed by the detection of fungal hyphae on a microscopic potassium hydroxide (koh) wet mount * participants must be in good general health and free of any disease that might interfere with study evaluations * participants with the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study exclusion criteria: * female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial * participants who are immunocompromised * participants who have a recent history of or currently known drug or alcohol abuse * participants with a history of intolerance or hypersensitivity to imidazole compounds, proton pump inhibitors, or the inactive components of luliconazole cream 1% or omeprazole * participants with a life-threatening condition within the last 6 months * participants with uncontrolled diabetes mellitus * participants who are unable to communicate or cooperate with the investigator * participants using medications for treatment of tinea pedis and/or tinea cruris (see investigator for length of time prior to study start) * participants receiving concomitant drugs that are known to inhibit and/or induce cyp2c19 and/or cyp3a4, or that interact with omeprazole * because of the potential for drug interaction with luliconazole, administration with medications that are known to be substrates of cyp3a4, cyp2b6, cyp2c8, and cyp2c19 should be carefully monitored
vapocoolant spray used prior to intravenous (iv) insertions

Conditions: Pain

Summary: the primary purpose of this study is to determine if by offering a vapocoolant (cold spray) to hospital outpatients prior to an intravenous catheter (iv) insertion will increase patient satisfaction of iv insertion as well as determine if pain of insertion is decreased.

this is a single blind interventional study with a post design using a convenience sample of patients undergoing a nuclear medicine stress test. the patient selection and intervention will be randomized in order to ensure a high validity study. the interventional treatment used will be a ethyl chloride mist spray manufactured by the gebauer company. the placebo spray that will be used is manufactured by biologic aqua research technologies international inc. the spray is called nature's tears mist and is a sterile water. the patient's for this study are required to have intravenous cannulation (iv) access. this is a painful and invasive procedure in which a vapocoolant may confer benefit for the relief of pain.

Eligibility criteria:
inclusion criteria: * any outpatient ordered to undergo a nuclear medicine stress test and is required to have iv access for injection of radiopharmaceuticals exclusion criteria: * if it is the first time the patient has had an intravenous catheter inserted * any patient who is or may be pregnant * any patient who is breast-feeding * any patient who has taken a narcotic, sedative and/or anti-anxiety medication within 8 hours of intervention time. * any patient who has a known diagnosis of raynaud's syndrome or carpal tunnel syndrome. * any patient who has an allergy or hypersensitivity to ethyl chloride. * any patient under the age of 18 and/or any patient over the age of 85 * any patient who is illiterate * any patient who is non-english speaking * any patient with prior experience with a vapocoolant spray.

Keywords: vapocoolant applied prior to iv access
voice acoustic properties in people with obstructive sleep apnea syndrome (osas)

Conditions: Obstructive Sleep Apnea of Adult

Summary: the aim of this study is to examine whether voice acoustic properties has an influence on sleep apnea. sleep apnea syndrome is defined as a sudden stop of more than ten seconds multiple times during sleep. the syndrome is common especially among men and occurs in 2%-4% of the population aged 30-60. the syndrome diagnosis is performed by an ent (ear, nose and throat) physician. the diagnosis is based on evaluation of anatomical structures in the sound path (nose and throat, jaw, pharynx and oral cavity) and a polysomnography (psg) test which quantifies the number and duration of breathing pauses during night sleep and additional parameters that monitor sleep. the syndrome has many negative consequences for those who suffer from it, including fatigue , lack of concentration, hypertension, diabetes ,heart disease, stroke and even death. therefore, early diagnosis is important.


Eligibility criteria:
inclusion criteria: * 18 years and older men who meet the criteria for disorders such as apnea. * 18 years old men and older who meet the criteria of snores based on screening questionnaires. * 18 years old men and older who don't suffer from disorders such as apnea and do not suffer from snoring. exclusion criteria: * smoking patients or smoked in the past. * having neurological disorders. * having swallowing trouble. * having respiratory problems. * having neuroendocrine problems. * having voice disorders. * patients who were previously head or/and neck operated
ingrown toenails : surgery only versus surgery + chemical cauterization with tca

Conditions: Relapse; Quality of Life; Complication; Pain, Postoperative

Summary: ingrown toenail is a very common disease in the general population that touches young adults. there are lots of treatments from local care of pedicure to surgery with matricectomy. gold standard of symptomatic and painful ingrown toenail is the simple surgery with matricectomy and with suture or directed healing pad. for many years chemical cauterisation with phenolic acid is used, a method with very few relapses and with a more simple pad. however, because of a lack of information about this phenolic acid, the pharmaceutical laboratory withdrew it from the market. the new method to replace phenolic acid is trichloroacetic acid, used mainly in cosmetics for peeling. this method was already compared to phenolic acid and showed equal results with fewer laps of application and a low cost. the comparison between acid trichloroacetic method and the gold standard surgery was never done and will be the goal of this study. it's an open, non randomised, comparative, multicentric (2 centers) study with two groups : common surgery and surgery with chemical cauterisation for this study the investigators will compare between the two groups : gain of quality of life at one month after surgery, difference of pain between before, one week and one month after surgery, the occurrence of adverse events and number of relapses at one year.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ingrown toenail * patient informed and with signed informed consent exclusion criteria: * medical history of ingrown toenail on the concerned nail * other nail disease * pregnancy * allergy to local anesthetic or to trichloroacetic acid

Keywords: ingrown nail simple surgery surgery with chemical cauterisation trichloroacetic acid relapse quality of life
characterization of bovine adrenal medulla (bam8-22) as a new surrogate model of non-histaminergic itch

Conditions: Itch

Summary: with this experiment, the experimenter wish to create a new model of itch based on the substance bam8-22 (bovine adrenal medulla), which is found naturally in the human body and which has proved to evoke itch.

with this experiment, the experimenter wish to create a new model of itch based on the substance bam8-22 (bovine adrenal medulla), which is found naturally in the human body and which has proved to evoke itch.to explore and validate the dose-response features of a of this new itch model based on bam8-22. the experimenter will also characterize the sensory quality and temporary aspects of bam8-22 skin prick test (spt) in comparison to the inactivated-cowhage delivery system.

Eligibility criteria:
inclusion criteria: * healthy men and women * 18-60 years * speak and understand english exclusion criteria: * pregnancy or lactation * drug addiction defined as any use of cannabis, opioids or other drugs * previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.) * moles, wounds, scars or tattoos in the area to be treated or tested * lack of ability to cooperate • * current use of medications that may affect the trial such as antihistamines and pain killers. * skin diseases * consumption of alcohol or painkillers 24 hours before the study days and between these - acute or chronic pain • * participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)
a new treatment approach for major depressive disorder based upon targeting monoamine oxidase a (mao-a)

Conditions: Major Depressive Disorder

Summary: the investigators will be looking at mao-a density before and after seven weeks of treatment with an antidepressant and dietary supplement. mao-a is an enzyme that breaks down brain chemicals that regulate mood. mao-a density is elevated in patients with major depressive episodes (mde) secondary to major depressive disorder (mdd). many remain treatment resistant with common antidepressant treatments and we think it may be due to poor targeting of brain pathologies. we want to test if adding a dietary supplement may normalize mao-a.

all subjects are getting the combined treatment of a selective serotonin reuptake inhibitor and the dietary supplement. there are two possible selective serotonin reuptake inhibitor treatments but the dietary supplement remains the same. no subjects are receiving the selective serotonin reuptake inhibitor alone and no subjects are receiving the dietary supplement alone. the dietary supplement is called n-acetylcysteine.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of current major depressive episode and major depressive disorder * hamilton depression rating scale score of at least 20 exclusion criteria: * comorbid axis i or ii disorders * antidepressant use in past 6 months * current use of herbal remedies * cigarette smoking * drug or medication use within past 8 weeks * history of substance abuse/neurotoxin use * history of psychotic symptoms * history of cns medical illness * current substance use * test positive on pregnancy test (women)
biologic abatement and capturing kids' outcomes and flare frequency in juvenile spondyloarthritis

Conditions: Juvenile Spondyloarthritis

Summary: this randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (tnfi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. this open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (aim 1) and patients' lived experiences (aim 2) across three arms.

this project is a prospective, 12-month pragmatic randomized trial embedded within routine clinical care. children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a tnfi for 6 months or longer will be eligible for enrollment. children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of tnfi (arm 2), or stopping tnfi (arm 3). the recommended visit frequency is every 3 months through the study endpoint at 12 months. after subjects have followed their treatment assignment for 12 months, those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. all participants will be monitored for 24 additional months for long-term outcomes after the intervention period.

Eligibility criteria:
inclusion criteria: 1. males or females age 8 to 21 years 2. juvenile spa diagnosis (symptom onset before their 16th birthday): pediatric rheumatology international trials organization (printo) revision of the the international league of associations for rheumatology (ilar) criteria enthesitis/spondylitis-related juvenile idiopathic arthritis (jia) * peripheral arthritis and enthesitis, or * arthritis or enthesitis, plus ≥ 3 months of inflammatory back pain and sacroiliitis on imaging, or * arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of human leukocyte antigen (hla-b27) ; (4) acute (symptomatic) anterior uveitis; and (5) history of a spa in a first-degree relative 3. currently taking one of the following tnfi therapies (adalimumab, certolizumab, etanercept, golimumab, infliximab) at standard doses and dosing intervals 4. have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician 5. english speaking or spanish speaking 6. interested and willing to de-escalate tnfi therapy exclusion criteria: 1) history of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of tnfi therapy or psoriasis that started after tnfi therapy and has required more than topical therapy for control
a prospective, double-blinded, randomized controlled trial of dhacm for incisional hernia prophylaxis

Conditions: Incisional Hernia

Summary: currently, no standard of care exists to prevent incisional hernias (ih). this study will compare how frequently ih develop in standard abdominal closures vs. abdominal closures with dhacm added. by adding dhacm to the standard closure, we think we can reduce the formation of ih. if patients decide to participate in this study, they will be randomly assigned to one of two study arms, arm a or arm b. they will have a 50% chance of being assigned to either arm. the assignment will be made by computer program and is completely random. patients are not informed of which arm they are assigned. arm a (treatment arm): dhacm patients enrolled in this arm will have a thin sheet of dhacm placed as an overlay over the length of the closed incisions. dhacm is dehydrated human amniotic-chorion membrane. it is a fda-registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns. arm b (control arm) patients enrolled in this arm will have standard fascial closure. data collection will be performed at routine follow-up outpatient clinic visits with the primary surgeon to assess for ih related symptoms. at 6 months after surgery, patients will see a surgeon who is blinded to the randomization. this surgeon will perform a painless handheld ultrasound examination of the incision site.

two million laparotomies are performed annually in the united states (us). following these surgeries, the incidence of new incisional hernias (ih) is estimated at 400,000 cases per year. these hernias are a major source of morbidity and mortality for patients, and they result in $6-10 billion per year in healthcare costs. our multidisciplinary hernia prevention group has identified a novel ih prevention strategy in the form of dehydrated human amniotic-chorionic membrane (dhacm). we previously showed that dhacm prevents ih in animal models, and subsequently in a prospective cohort of high-risk patients. the purpose of this trial is to quantify the efficacy of dhacm in ih prophylaxis by performing a prospective, double-blinded randomized controlled trial. our specific aim is to test the hypothesis that augmentation of standard abdominal fascia closures with prophylactic, onlay dhacm sheets without fixation will reduce ih formation in a high-risk population.

Eligibility criteria:
inclusion criteria: * patient \> 18 years * written informed consent * non-emergent operation * predicted incisional herna (ih) risk ≥150% of the average ih risk, as calculated by the university of pennsylvania hernia risk calculator, which accounts for 18 ih risk factors * bmi \> 27 yields ih risk \> 150% of the average ih risk; this can be used as a shortcut for screening potential subjects exclusion criteria: * previous intraperitoneal mesh placement * previous abdominal incisional hernia * emergency procedures * patients with inflammatory bowel disease

Keywords: amniotic membrane placenta-derived tissue incisional hernia